Patents by Inventor Johannes Gerardus Maria EVERS

Johannes Gerardus Maria EVERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-GD2 antibody
    Patent number: 11866511
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 9, 2024
    Assignee: TigaTX, Inc.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers
  • ENGINEERED IGA ANTIBODIES AND METHODS OF USE
    Publication number: 20210395395
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Application
    Filed: June 9, 2021
    Publication date: December 23, 2021
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS, Geert Jan VAN TETERING
  • ENGINEERED IGA ANTIBODIES AND METHODS OF USE
    Publication number: 20210380720
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Application
    Filed: June 9, 2021
    Publication date: December 9, 2021
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS, Geert Jan VAN TETERING
  • Engineered IGA antibodies and methods of use
    Patent number: 11091562
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 17, 2021
    Assignee: UMC Utrecht Holding B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • Engineered IgA antibodies and methods of use
    Patent number: 11059909
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 13, 2021
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA
    Publication number: 20210179732
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 17, 2021
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS
  • ENGINEERED IGA ANTIBODIES AND METHODS OF USE
    Publication number: 20210130462
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 6, 2021
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS, Geert Jan VAN TETERING
  • ENGINEERED IGA ANTIBODIES AND METHODS OF USE
    Publication number: 20210122834
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: April 29, 2021
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS, Geert Jan VAN TETERING
  • ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA
    Publication number: 20200283541
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 10, 2020
    Inventors: Jeanette Henrica Wilhelmina LEUSEN, Johannes Gerardus Maria EVERS